We specifically identified somatic mutations that are predicted to disrupt miRNA target sites within genes, including TAL1, SCG3, and GSDMA, that are over-expressed in cancer and mutations that are predicted to create new miRNA target sites within genes, including MITF and EPHA3, that are underexpressed in cancer. This evidence concerns the gene TAL1 and cancer.